blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3820499

EP3820499 - TISSUE-SPECIFIC WNT SIGNAL ENHANCING MOLECULES AND USES [Right-click to bookmark this link]
StatusRequest for examination was made
Status updated on  16.04.2021
Database last updated on 30.10.2024
FormerThe international publication has been made
Status updated on  18.01.2020
Most recent event   Tooltip05.09.2024New entry: Additional fee for renewal fee: despatch of communication + time limit 
Applicant(s)For all designated states
Surrozen Operating, Inc.
171 Oyster Point Blvd. Suite 400
South San Francisco, CA 94080 / US
[2022/03]
Former [2021/20]For all designated states
Surrozen, Inc.
171 Oyster Point Blvd. Suite 400
South San Francisco, California 94080 / US
Inventor(s)01 / ZHANG, Zhengjian
c/o Surrozen, Inc. 171 Oyster Point Blvd., Suite
400 South
San Francisco, California 94080 / US
02 / LI, Yang
c/o Surrozen, Inc. 171 Oyster Point Blvd., Suite
400 South
San Francisco, California 94080 / US
03 / YEH, Wen-Chen
c/o Surrozen, Inc. 171 Oyster Point Blvd., Suite
400 South
San Francisco, California 94080 / US
04 / YUAN, Tom Zhiye
c/o Surrozen, Inc. 171 Oyster Point Blvd., Suite
400 South
San Francisco, California 94080 / US
05 / BARIBAULT, Helene
c/o Surrozen, Inc. 171 Oyster Point Blvd., Suite
400 South
San Francisco, California 94080 / US
06 / LAI, Kuo-Pao (Jimmy)
c/o Surrozen, Inc. 171 Oyster Point Blvd., Suite
400 South
San Francisco, California 94080 / US
 [2021/20]
Representative(s)Cooley (UK) LLP
22 Bishopsgate
London EC2N 4BQ / GB
[N/P]
Former [2021/20]Cooley (UK) LLP
Dashwood
69 Old Broad Street
London EC2M 1QS / GB
Application number, filing date19833402.109.07.2019
[2021/20]
WO2019US41067
Priority number, dateUS201862695509P09.07.2018         Original published format: US 201862695509 P
US201862770026P20.11.2018         Original published format: US 201862770026 P
US201962822731P22.03.2019         Original published format: US 201962822731 P
[2021/20]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2020014271
Date:16.01.2020
Language:EN
[2020/03]
Type: A1 Application with search report 
No.:EP3820499
Date:19.05.2021
Language:EN
The application published by WIPO in one of the EPO official languages on 16.01.2020 takes the place of the publication of the European patent application.
[2021/20]
Search report(s)International search report - published on:US16.01.2020
(Supplementary) European search report - dispatched on:EP10.06.2022
ClassificationIPC:A61K38/17, C07K16/18, C07K16/28, A61P1/16
[2022/28]
CPC:
C07K16/28 (EP,US); A61P1/16 (EP,US); C07K14/47 (US);
C07K16/2851 (EP); A61K2039/505 (EP); C07K2317/52 (EP);
C07K2317/55 (EP); C07K2317/565 (US); C07K2317/622 (EP,US);
C07K2317/70 (EP); C07K2317/76 (EP); C07K2317/92 (EP);
C07K2319/00 (EP); C07K2319/81 (US) (-)
Former IPC [2021/20]A61K38/17, C07K16/18, C07K16/28
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2021/20]
TitleGerman:GEWEBESPEZIFISCHE, WNT-SIGNAL-VERSTÄRKENDE MOLEKÜLE UND VERWENDUNGEN[2021/20]
English:TISSUE-SPECIFIC WNT SIGNAL ENHANCING MOLECULES AND USES[2021/20]
French:MOLÉCULES D'AMÉLIORATION DE SIGNAUX WNT SPÉCIFIQUES AU TISSU ET LEURS UTILISATIONS[2021/20]
Entry into regional phase08.02.2021National basic fee paid 
08.02.2021Search fee paid 
08.02.2021Designation fee(s) paid 
08.02.2021Examination fee paid 
Examination procedure08.02.2021Examination requested  [2021/20]
31.01.2023Despatch of communication that the application is deemed to be withdrawn, reason: reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report not received in time
11.04.2023Amendment by applicant (claims and/or description)
Request for further processing for:The application is deemed to be withdrawn due to failure to reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report/Supplementary European search report
11.04.2023Request for further processing filed
11.04.2023Full payment received (date of receipt of payment)
Request granted
20.04.2023Decision despatched
Fees paidRenewal fee
26.07.2021Renewal fee patent year 03
27.07.2022Renewal fee patent year 04
26.07.2023Renewal fee patent year 05
Penalty fee
Additional fee for renewal fee
31.07.202406   M06   Not yet paid
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[XI]WO2013054307  (NOVARTIS AG [CH]) [X] 17-20 * abstract, p. 2 [0009] - p. 4 [0016], p. 46 [0174] - p. 48 [0183], SEQ ID NOs 5, 6, 69, 70, 89, 90, and claims * [I] 1-16,21;
 [I]WO2014023709  (ROCHE GLYCART AG [CH]) [I] 1-21 * abstract, p. 2 line 10 - p. 6 line 32, examples p. 60 line 4 - p. 88 line 22, SEQ ID NOs 10, 12, 14, 16, 18, 20, 26, 28, 62, 64, 66, 68, 70, 72, 74, 76, 78, 86, 88, 90 and claims *;
 [XI]WO2015164392  (STEMCENTRX INC [US]) [X] 17-20 * abstract, p. 2 line 11 - p. 4 line 27, examples 1-18, SEQ ID NO: 78, 80, 273 and 275, and claims * [I] 1-16,21;
 [A]WO2017069628  (MERUS NV [NL], et al) [A] 1-21 * the whole document *;
 [XI]WO2018107116  (ABBVIE STEMCENTRX LLC [US]) [X] 17-20 * abstract, p. 2 line 20 - p. 9 line 3, examples 1-12, SEQ ID NO: 170, 171, 268, 269, 277, 278 and claims * [I] 1-16,21;
 [A]  - Jacquelyn O Russell ET AL, "Annual Review of Pathology: Mechanisms of Disease Wnt/β-Catenin Signaling in Liver Development, Homeostasis, and Pathobiology", Annu. Rev. Pathol. Mech. Dis, doi:10.1146/annurev-pathol-020117-, (20171110), pages 351 - 78, URL: https://www.annualreviews.org/doi/pdf/10.1146/annurev-pathol-020117-044010, (20200525), XP055698055 [A] 1-21 * the whole document *

DOI:   http://dx.doi.org/10.1146/annurev-pathol-020117-
 [A]  - TAO GUO-ZHONG ET AL, "Wnt/[beta]-Catenin Signaling Protects Mouse Liver against Oxidative Stress-induced Apoptosis through the Inhibition of Forkhead Transcription Factor FoxO3", JOURNAL OF BIOLOGICAL CHEMISTRY, US, vol. 288, no. 24, doi:10.1074/jbc.M112.445965, ISSN 0021-9258, (20130425), pages 17214 - 17224, URL: https://www.jbc.org/action/showPdf?pii=S0021-9258(20)45867-3, XP055925579 [A] 1-21 * the whole document *

DOI:   http://dx.doi.org/10.1074/jbc.M112.445965
 [A]  - SHILPI SATISH ET AL, "Drug targeting strategies for liver cancer and other liver diseases", MOJ DRUG DESIGN DEVELOPMENT & THERAPY, vol. 2, no. 4, (20180703), pages 171 - 177, URL: https://medcraveonline.com/MOJDDT/MOJDDT-02-00044.pdf, XP055925577 [A] 1-21 * the whole document *
 [A]  - PEREZ DE LA LASTRA ET AL, "Epitope mapping of 10 monoclonal antibodies against the pig analogue of human membrane cofactor protein (MCP)", IMMUNOLOGY, GB, (19990401), vol. 96, no. 4, doi:10.1046/j.1365-2567.1999.00732.x, ISSN 0019-2805, pages 663 - 670, XP055572134 [A] 1-21 * abstract, p. 664 right-hand column line 12 - p. 665 left-hand column second full paragraph, p. 665 right-hand column two last lines - p. 667 right-hand column first full paragraph and discussion *

DOI:   http://dx.doi.org/10.1046/j.1365-2567.1999.00732.x
 [T]  - ZHANG ZHENGJIAN ET AL, "Tissue-targeted R-spondin mimetics for liver regeneration", SCIENTIFIC REPORTS, vol. 10, no. 1, doi:10.1038/s41598-020-70912-3, (20200818), URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7435267/pdf/41598_2020_Article_70912.pdf, XP055926092 [T] * the whole document *

DOI:   http://dx.doi.org/10.1038/s41598-020-70912-3
International search[A]WO2012140274  (KONINKLIJKE NEDERLANDSE AKADEMIE VAN WETENSCHAPPEN [NL], et al) [A] 1-3, 46-51, 53 * entire document *;
 [A]WO2013054307  (NOVARTIS AG [CH]) [A] 1-3, 46-51, 53 * entire document *;
 [A]WO2015164392  (STEMCENTRX INC [US]) [A] 1-3, 46-51, 53 * entire document *;
 [A]WO2017100467  (REGENERON PHARMA [US]) [A] 1-3, 46-51, 53 * entire document *;
 [X]US2017240633  (WANG CHENG-I [SG], et al) [X] 1, 2, 49-51, 53 * entire document *;
 [PA]WO2018140821  (SURROZEN INC [US]) [PA] 1-3, 46-51, 53* entire document *
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.